Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Vaccine

• Publication date

  2009-12-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2009.09.135PMID 19857446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccine prevention of maternal cytomegalovirus infection.

  2009cited by this paper
• Therapeutic and prophylactic applications of alphavirus vectors

  2008cited by this paper
• T-cell quality in memory and protection: implications for vaccine design

  2008cited by this paper
• Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

  2008cited by this paper
• Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins

  2007cited by this paper
• Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

  2007cited by this paper
• Cytomegalovirus infections.

  2007cited by this paper
• Cytomegalovirus Infection

  2007cited by this paper
• A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses

  2007cited by this paper
• Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

  2007cited by this paper
• Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.

  2007cited by this paper
• Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles

  2005cited by this paper
• Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

  2005cited by this paper
• Passive immunization during pregnancy for congenital cytomegalovirus infection.

  2005cited by this paper
• Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

  2004cited by this paper
• Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.

  2004cited by this paper
• Congenital cytomegalovirus infection: epidemiology and treatment.

  2004cited by this paper
• Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.

  2004cited by this paper
• Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

  2004influential reference
• Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-tumor Immunity to the ‘Self’ tumor-associated antigen, neu in a Rat Mammary Tumor Model

  2003cited by this paper
• Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.

  2002cited by this paper
• Alphavirus vectors and vaccination

  2002cited by this paper
• Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection

  2001cited by this paper
• A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.

  2001cited by this paper
• Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.

  2000cited by this paper
• Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence.

  1999cited by this paper
• A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

  1999cited by this paper
• Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.

  1999cited by this paper
• A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

  1999cited by this paper
• Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation

  1997cited by this paper
• DNA immunization confers protection against murine cytomegalovirus infection

  1996cited by this paper
• Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

  1995cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

  1992cited by this paper
• Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

  1988cited by this paper
• Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

  1987cited by this paper
• Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.

  1984cited by this paper

• High-throughput epitope screening of the Human Cytomegalovirus immediate early protein 2 identifies promising antigenic T cell targets

  2026cites this paper
• mRNA technology for the prevention and treatment of HIV-1 infection

  2026cites this paper
• A vaccine against cytomegalovirus: how close are we?

  2025cites this paper
• Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

  2025cites this paper
• Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer

  2025cites this paper
• Safety, Immunogenicity, and Efficacy of Cytomegalovirus Vaccines: A Systematic Review of Randomized Controlled Trials

  2025cites this paper
• Optimized multi-epitope neoantigen human cytomegalovirus vaccine based on adenovirus vectors elicits potent antiviral immunity

  2025cites this paper
• A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial

  2025cites this paper
• Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV’s Immunological Achilles’ Heel

  2025cites this paper
• Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo

  2024cites this paper
• Human cytomegalovirus: pathogenesis, prevention, and treatment

  2024cites this paper
• Cytokine responses to major human Cytomegalovirus antigens in mouse model.

  2024cites this paper
• RNA therapeutics for infectious diseases.

  2024cites this paper
• Cytomegalovirus Disease as a Risk Factor for Invasive Fungal Infections in Liver Transplant Recipients under Targeted Antiviral and Antimycotic Prophylaxis

  2023cites this paper
• Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

  2023cites this paper
• Advances in mRNA vaccines for viral diseases

  2023cites this paper
• Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

  2022cites this paper
• Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon

  2022cites this paper
• Next generation self-replicating RNA vectors for vaccines and immunotherapies

  2022cites this paper
• mRNA delivery technologies: Toward clinical translation.

  2022cites this paper
• Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.

  2022cites this paper
• Advances in mRNA vaccines

  2022cites this paper
• Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

  2022cites this paper
• Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens

  2022cites this paper
• Application of Viruses for Gene Therapy and Vaccine Development

  2022cites this paper
• Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies

  2022cites this paper
• Design Optimization and Immune Kinetics of mRNA Vaccines

  2022cites this paper
• The Delivery of mRNA Vaccines for Therapeutics

  2022cites this paper
• Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity

  2021cites this paper
• In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients

  2021cites this paper
• Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

  2021cites this paper
• Alphavirus-Based Antigen Preparation.

  2021cites this paper
• Novel approaches for vaccine development.

  2021cites this paper
• Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.

  2021cites this paper
• The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview

  2021cites this paper
• mRNA vaccine for cancer immunotherapy

  2021cites this paper
• Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.

  2021cites this paper
• Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

  2021cites this paper
• Cytomegalovirus

  2020cites this paper
• Cytomegalovirus and Epstein–Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development

  2020cites this paper
• A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus

  2020cites this paper
• Current status of vaccines against congenital cytomegalovirus infection: The paradox of previous immunity

  2020cites this paper
• Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio

  2020cites this paper
• Self-Amplifying RNA Viruses as RNA Vaccines

  2020cites this paper
• Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

  2020cites this paper
• Estado actual de las vacunas frente a la infección congénita por citomegalovirus: la paradoja de la inmunidad previa

  2020cites this paper
• Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

  2020cites this paper
• Formulation and Delivery Technologies for mRNA Vaccines.

  2020cites this paper
• Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats

  2020cites this paper
• Viral replicons as valuable tools for drug discovery

  2020cites this paper
• An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

  2020cites this paper
• Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

  2020cites this paper
• Subcutaneous vaccine administration – an outmoded practice

  2020cites this paper
• Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance

  2020cites this paper
• MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission

  2019cites this paper
• Vaccination against the human cytomegalovirus

  2019cites this paper
• Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.

  2019cites this paper
• Development of novel vaccines against human cytomegalovirus

  2019cites this paper
• Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.

  2019cites this paper
• Gene Therapy Today and Tomorrow

  2019cites this paper
• RNA Viruses as Tools in Gene Therapy and Vaccine Development

  2019cites this paper
• Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

  2019cites this paper
• mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

  2019cites this paper
• Plasmid DNA-Based Alphavirus Vaccines

  2019cites this paper
• Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

  2018cites this paper
• Self-Replicating RNA Viruses for RNA Therapeutics

  2018cites this paper
• An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

  2018cites this paper
• Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform

  2018cites this paper
• 16 – Cytomegalovirus Vaccines

  2018cites this paper
• Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

  2018cites this paper
• Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

  2018cites this paper
• An analysis of human cytomegalovirus gene family function

  2018cites this paper
• Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

  2018cites this paper
• 66 – Technologies for Making New Vaccines

  2018cites this paper
• Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections

  2018cites this paper
• Development of a Broadly Accessible VEE Replicon Particle Vaccine Platform

  2018cites this paper
• Vaccine Development for Cytomegalovirus.

  2018cites this paper
• Mechanism of action of mRNA-based vaccines

  2017cites this paper
• In vitro evaluation of a polytope DNA construct as a novel DNA vaccine strategy against human cytomegalovirus-associated diseases.

  2017cites this paper
• Alphavirus-Based Vaccines.

  2017cites this paper
• Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection

  2017cites this paper
• Long-term Survival in Glioblastoma with Cytomegalovirus pp 65-Targeted Vaccination

  2017cites this paper
• Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP)

  2017cites this paper
• Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX

  2017cites this paper
• Development of biomaterial porous scaffolds for dendritic cell modulation and mRNA delivery

  2017cites this paper
• Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation.

  2017cites this paper
• Towards RNA Nanoparticle Vaccines: Synergizing RNA and Inorganic Nanoparticles to Achieve Immuno-potentiation

  2017cites this paper
• Fate of antigens encoded by Self-amplifying mRNA vaccines

  2017cites this paper
• Establishment and validation of an enzyme-linked immunosorbent assay for IgG antibody against cytomegalovirus based on pp150 antigen.

  2017cites this paper
• Humoral responses to Cytomegalovirus glycoprotein B vaccine with MF59 adjuvant

  2017cites this paper
• Development of a vaccine against cytomegalovirus infection and disease.

  2017cites this paper
• Development of Gene-Based Vectors for Immunization

  2017cites this paper
• The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development.

  2017cites this paper
• Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

  2017cites this paper
• Cytomegalovirus infection in pregnancy

  2017cites this paper
• Investigating and exploiting the latency-associated expression of the human cytomegalovirus gene US28 in early myeloid lineage cells.

  2017cites this paper
• Self-replicating RNA viral vectors in vaccine development and gene therapy

  2016cites this paper
• Viral vector-based influenza vaccines

  2016cites this paper
• Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

  2016cites this paper
• Congenital Cytomegalovirus: a “Now” Problem—No Really, Now

  2016cites this paper